Canaccord raised the firm’s price target on GeneDx (WGS) to $160 from $155 and keeps a Buy rating on the shares. The firm said they remain bullish after another quarter of solid execution and continued profitable growth, driving increased long-term estimates. Canaccord noted GeneDx’s strategy to convert existing customers to WES/WGS and ramp new indications is driving solid growth.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- GeneDx price target raised to $170 from $115 at Guggenheim
- Genedx Holdings Corp. Maintains Stable Risk Profile in 2025 Reports
- GeneDx Reports Strong Q3 2025 Financial Growth
- GeneDx’s Earnings Call Highlights Robust Growth and Optimism
- GeneDx Holdings: Strong Q3 Performance and Strategic Expansion in Pediatric Market Drive Optimistic Outlook